

# ICPO THERANOSTICS VIRTUAL SUMMIT 2024

## New Era of Alpha Emitters and Radiopharmaceuticals



Preliminary Program (Version July 10, 2024)

### Day 1, November 14, 2024

**Alpha Emitters with focus on Ac225, At211 and Pb212 // Latest innovation and clinical establishment today // Patient access and global perspective.**

2:00 pm - 2:20 pm	Welcome
2:20 pm - 2:40 pm	<b>Keynote: History of Alpha Therapy</b> S. Larson (USA)
2:40 pm - 3:25 pm	<b>SESSION I: Alpha Emitters 101</b> <ul style="list-style-type: none"><li>• Radiobiology need to know about Alphas - J-P. Pouget (France)</li><li>• Dosimetry techniques for alpha radioligand therapy: where are we now? - P. Fragoso Costa (Germany)</li><li>• Radiochemistry Alpha specificities and latest advances - M. Nader (Germany)</li></ul>
3:25 pm - 4:25 pm	<b>SESSION II: Alpha Emitters from Bench to Bed Side</b> <ul style="list-style-type: none"><li>• Ac225 Clinical Insights from WARMTH Act LANCET Oncology Study - M. Sathekge (South Africa)</li><li>• At211 from preclinical to the clinic - T. Watabe (Japan)</li><li>• Pb212 Preclinical Experience and Clinical Potential - N. Pullen (Switzerland)</li><li>• Pb212 PSMA Clinical experience in prostate cancer and isotope considerations for novel targets, binders and indications" A. Karmann (USA)</li></ul>
<b>4:25 pm - 4:35 pm</b>	<b>BREAK</b>
4:35 pm - 5:20 pm	<b>SESSION III : Alpha Emitters beyond PSMA</b> <ul style="list-style-type: none"><li>• Innovation in Ac225 Supply - TBC</li><li>• Next-generation SSTR2 targeting in Small Cell Lung Cancer with Ac-225 -G. Gericke (Germany)</li><li>• Pb212 Dotamate in NET - E. Delpassand (USA)</li></ul>
5:20 pm - 6:35 pm	<b>SESSION IV: Challenges of Alpha therapies versus conventional emitters</b> <ul style="list-style-type: none"><li>• Global supply status and challenges of Ac225 and other alphas - Neil Quigley (Germany)</li><li>• At211 the European Network - J-F Gestin (France)</li><li>• Pb212 Generators: Different Concepts &amp; Logistics - M. Schultz (USA)</li><li>• Regulatory Perspective on the Introduction on Alpha Therapies - TBC</li><li>• Ethics in Clinical trials on Alpha Therapies - J. Mailman (USA)</li></ul>
6:35 pm - 7:20 pm	<b>PANEL 1: Global perspective on patient access today and in 5 years</b> Moderators: R.P. Baum and F. Giesel (Germany)
7:20 pm - 7:30 pm	<b>Wrap up and Closing of Day 1</b>

# ICPO THERANOSTICS VIRTUAL SUMMIT 2024

## New Era of Alpha Emitters and Radiopharmaceuticals



Preliminary Program (Version July 10, 2024)

### Day 2, November 15, 2024

#### Radiopharmaceuticals with focus on FAP, CA9, CXCR4 and GPC3 // From trials to clinical profiles // Patient access and global perspective

9:00 am - 9:10 am	Welcome
9:10 am - 9:30 am	<b>Keynote: History of FAP till today</b> A. Scott (Australia)
9:30 am - 10:45 am	<b>SESSION V: FAP Diagnostics in Oncology and non-Oncology</b> <ul style="list-style-type: none"><li>FAP Dx into clinical practice today – malignant and non-malignant - F. Giesel (Germany)</li><li>Myocardial and Organ Fibrosis - TBC</li><li>FAP Dx Some On-going Clinical Trials - S. Mosessian (USA)</li></ul>
10:45 am - 11:30 am	<b>SESSION VI: FAP Therapy</b> <ul style="list-style-type: none"><li>FAP Peptide Targeted Tx - R.P. Baum (Germany)</li><li>FAP Dimer - S. Ballal (India)</li><li>Optimisation of FAP ligands for therapy through multimerization and medicinal chemistry approaches - J. Mock (Switzerland)</li></ul>
11:30 am - 10:50 am	<b>PANEL 2: FAP as Imaging Biomarker</b> Moderator: E. Zan (USA)
<b>11:50 am - 12:00 am</b>	<b>BREAK</b>
12:00 am - 12:45 am	<b>SESSION VII: CA9</b> <ul style="list-style-type: none"><li>G250 Antibody Renal Cell Cancer - S.T. Lee (Australia)</li><li>CA9 Theranostics with Small Molecules - M. Hofman (Australia)</li><li>CA9 Some On-going Clinical Trials - D. Cade and S. Gribble (Australia)</li></ul>
12:45 am - 1:45 pm	<b>SESSION VIII: CXCR4 and GPC3</b> <ul style="list-style-type: none"><li>CXCR4 Hematological Indications - R. Werner (Germany)</li><li>CXCR4 some On-going Clinical Trials - H. Bouterfa (Germany)</li><li>GPC3 Promise for Oncology - W. Weber (Germany)</li><li>GPC1 Promise for Oncology - S. Serada (Japan)</li></ul>
1:45 pm - 2:05 pm	<b>PANEL 3: Antibody Drug Conjugates contra Radiopharmaceutical Therapies?</b> Moderator: K. Herrmann (Germany)
2:05 pm - 2:50 pm	<b>FINAL ROUND TABLE: A new theranostics era for patients, fueled by innovation &amp; regulatory advances</b>
2:50 pm - 3:00 pm	<b>Wrap up and Closing of Summit 2024</b>